ORAL THERAPEUTICS AND PHARMACOLOGY
Online ISSN : 1884-4928
Print ISSN : 0288-1012
ISSN-L : 0288-1012
Search
Advanced search
OR
Browse
Search
Volume 34, Issue 1
Displaying 1-4 of 4 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
Review
Original Article
  • Clinical study of vitamin B12 therapy to Hunter glossitis
    YUGO KUROKI, YOSHIYUKI OKAMOTO, SHINNOSUKE ISHIBASHI, KENSUKE KAWADA, ...
    2015 Volume 34 Issue 1 Pages 9-15
    Published: April 01, 2015
    Released on J-STAGE: June 01, 2015
    DOIhttps://doi.org/10.11263/jsotp.15.02
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Hunter glossitis is a relatively rare disease caused by vitaminB12 deficiency. We clinically studied six cases of Hunter glossitis caused by vitamin B12 deficiency. All cases complained tongue pain and dysgeusia, and they showed atrophy of lingual papillae and vitamin B12 deficiency in blood examination. Macrocytic anemia was found out in five cases but one case was not anemia. Two cases were under treatment of chronic gastritis and three cases were total gastric resection in past. Untreated atrophic gastritis was found out in one case by upper gastrointestinal endoscopy. We treated all cases by oral administered vitamin B12 therapy 1500 µg/day. After this therapy, red smooth tongue, oral pain, dysgeusia and level of vitamin B12 in blood were improved in all cases.
    It is popular that the treatment of vitamin B12 deficiency is based on parenteral vitamin B12 administered intramuscular injection. But recently, a few reports documented positive results following oral vitamin B12 therapy. As the result of these cases, oral administered vitamin B12 therapy was effective to Hunter glossitis.
    View full abstract
    Download PDF (1373K)
Case Report
  • A case of SAPHO syndrome initially diagnosed as diffuse sclerosing osteomyelitis of the mandible and effectively treated by bisphosphonate
    KENJI SUZUKI, MASARU KOBAYASHI, SHIGEYUKI OZAWA, TADANORI KONDO, TAKEH ...
    2015 Volume 34 Issue 1 Pages 16-22
    Published: April 01, 2015
    Released on J-STAGE: June 01, 2015
    DOIhttps://doi.org/10.11263/jsotp.15.03
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Etiology of diffuse sclerosing osteomyelitis (DSO) of the mandible is still controversy. Whereas symptoms of DSO tend to recur after administration of antibiotics or surgery, an alternative hypothesis that DSO is a metabolic disorder due to osteoclasts has been proposed. We report a case of DSO effectively treated with pamidronate, a Bisphosphonate (BP), and finally diagnosed as SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome after 10 years of follow-up period.
    The patient is a 32-year-old male with DSO of the mandible showing resistance to long-term administration of antibiotics and hyperbaric oxygen therapy (HBO). After intravenous administration of pamidronate, pain disappeared completely, and the remarkable improvement of the bone structure of the mandible was confirmed by CT examination 5 months after the BP administration.
    After the 10 years of follow-up period, bone scintigram showed high-uptake at sternoclavicular joint as well as sacroiliac joint, and the patient was diagnosed as SAPHO syndrome. It is necessary to take that DSO is a part symptom of the SAPHO syndrome into consideration.
    View full abstract
    Download PDF (1315K)
Report from the Working Group
  • EBM of Kampo medicine in oral surgery
    PAO-LI WANG, MASATAKA SUNAGAWA, KOJIRO YAMAGUCHI, ATSUSHI KAMEYAMA, AK ...
    2015 Volume 34 Issue 1 Pages 23-30
    Published: April 01, 2015
    Released on J-STAGE: June 01, 2015
    DOIhttps://doi.org/10.11263/jsotp.15.04
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Kampo medicine has a long experience and actual performance over a long period of history. The first oriental medicine was approved by Japanese national health insurance in 1976, and 147 kinds of oriental medicine are currently approved by the National Health Insurance Drug Price. Those of 7 kinds of Kampo medicine were approved by Japan Dental Association of “National Health Insurance Drug Price Standard related with dental treatment” on April 2012. It has been reported that approximately 70 to 80％ of doctors has an experience to use oriental medicine in a clinical site. Meanwhile, oriental medicine was used at more than 85％ of medical facilities in a survey of Kampo medicine usage at oral surgery clinics in all Japanese Dental University hospital and Medical University hospital. However, only a few Kampo medicine was used at general dental clinics. Establishment of the evidence of oriental medical treatment in dental lesions is one of the solution of popularizing a treatment of Kampo medicine in oral surgery. Hence, efficacy of Kampo medicine which was approved by the new drug standard since 1986 was evaluated from the aspect of Evidence-based medicine（EBM）.
    View full abstract
    Download PDF (964K)
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top